Z19.2 — Hormone resistant malignancy status
Z19.2 is a billable, specific ICD-10-CM code for hormone resistant malignancy status. It is valid for submission on a claim.
Inclusion terms
Alternative wordings a physician may use in the chart for this same code.
- Castrate resistant prostate malignancy status
Risk adjustment
Z19.2 does not map to an HCC and does not risk-adjust under CMS-HCC V28. That is normal — most ICD-10 codes do not. It still needs to be coded correctly; it just will not move a RAF score.
Medicare coverage
Z19.2 is named in 8 Medicare coverage policies — 8 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A58021Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
- A58021Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
- A58063Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
- A58063Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells
How Z19.2 is indexed
Coders do not find codes by browsing the tabular list — they look them up in the alphabetic index, under the word the physician wrote. These are the index entries that lead here, so you can see which chart wordings map to Z19.2.
- Status›malignancy›castrate resistant prostate
- Status›malignancy›hormone resistant
Related codes at this level
Codes that share Z19. If Z19.2 is not quite right, the correct code is usually one of these.
Questions about Z19.2
- Is Z19.2 a billable ICD-10-CM code?
- Yes. Z19.2 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does Z19.2 sit in the tabular list?
- Factors influencing health status and contact with health services (Z00-Z99), in the block Hormone sensitivity malignancy status (Z19).